Drug Stocks Q4 Earnings Lineup for Feb 21: IRWD, MNTA, EXAS

Momenta’s bottom-line performance has been decent so far, with its earnings surpassing expectations in three of the last four quarters. However, over the trailing four quarters, the company has recorded an average negative surprise of 75.74%.